Clinical Study of Haploid Allogeneic Hematopoietic Stem Cell Transplantation Combined with Post-transplant Cyclophosphamide in Severe Aplastic Anemia Patients.
10.19746/j.cnki.issn.1009-2137.2022.01.038
- Author:
Jun-Nan LI
1
;
Ping LI
2
;
Lin LIU
1
;
Qing XIAO
1
;
Xiao-Qiong TANG
1
;
Hong-Bin ZHANG
1
;
Xin WANG
1
;
Xiao-Hua LUO
1
;
Li WANG
3
Author Information
1. Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
2. Department of Bone Orthopaedics, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China.
3. Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China,E-mail: 5640326@qq.com.
- Publication Type:Journal Article
- Keywords:
efficacy;
haploid allogeneic hematopoietic stem cell transplantation;
severe aplastic anemia
- MeSH:
Anemia, Aplastic/therapy*;
Cyclophosphamide;
Graft vs Host Disease;
Haploidy;
Hematopoietic Stem Cell Transplantation;
Humans;
Retrospective Studies;
Transplantation Conditioning
- From:
Journal of Experimental Hematology
2022;30(1):227-231
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the clinical effect of haploid allogeneic hematopoietic stem cell transplantation(haplo-HSCT) in the treatment of severe aplastic anemia (SAA), and to explore the efficacy different between post-transplant cyclophosphamide (PT/Cy) and standard-dose ATG.
METHODS:The clinical data of 38 patients with SAA in our hospital from January 2012 to December 2019 were collected and retrospectively analyzed. The efficacy was evaluated. The patients with haplo-HSCT were divided into low-dose ATG combined with PT/Cy group and standard-dose ATG group, and the blood cell hematopoietic reconstruction time, GVHD incidence, mortality and survival time of the patients in the two groups was compared.
RESULTS:Among the 32 patients, hematopoietic reconstitution were detected in 9375%(30/32) recipients. The median time of neutrophil and platelet engraftment was 15(10-22) days and 13(7-30) days, respectively. The incidence of GVHD was 21.89%, the incidence of infection was 93.75%, and the 2-year overall survival rate was 84.38%. The hematopoietic reconstitution time, incidence of GVHD, mortality rate and survival time were no statistical differences between the patients in the two groups(all P>0.05).
CONCLUSION:Haplo-HSCT is an effective method for the treatment of SAA，low-dose ATG combined with PT/Cy can lighten the economic burden on patients, it would be a feasible treatment plan for SAA with light side effect.
